Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2009

01.03.2009 | Clinical Trial

Nipple-sparing mastectomy: risk of nipple-areolar recurrences in a series of 579 cases

verfasst von: J. Y. Petit, U. Veronesi, P. Rey, N. Rotmensz, E. Botteri, M. Rietjens, C. Garusi, F. De Lorenzi, S. Martella, R. Bosco, A. Manconi, A. Luini, V. Galimberti, P. Veronesi, G. B. Ivaldi, R. Orecchia

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Background When the conservative treatment is not recommended, Nipple Sparing Mastectomy (NSM) is proposed more and more frequently for the surgical treatment of breast cancer. The risk of local recurrence behind the nipple areolar complex (NAC) is the main limiting factor of the NSM procedure. To minimize such risk, we proposed in 2002 a intraoperative radiotherapy of the preserved NAC. Patients and methods From March 2002 to November 2006, 579 cases (in 570 patients) of NSM were performed for carcinoma. The median follow up time was 19 months (Range: 1–60). The subcutaneous mastectomy was performed through an incision removing a portion of the skin overlying the tumour. An extemporaneous histological examination was performed on the retroareolar glandular tissue. If the histology was positive the patient was not considered eligible. Then an intraoperative radiotherapy with electrons (ELIOT) of 16 Gy in one shot was delivered on the NAC area. An immediate breast reconstruction was done using implants in most cases and in several cases a musculocutaneous flaps, usually in large breast. The number of local recurrences was recorded and the correlation between their occurrence and the clinical and histological criteria were analysed using the Gray test statistical method in a competing framework. Results In 516 cases the negative retroareolar frozen section biopsy was confirmed by the final histology, while in 63 cases, the final histology showed foci of carcinoma. Seven out of these 63 cases underwent a secondary NAC removal. In the 56 cases which preserved areolas we did not observe any local recurrence after 19 months follow up. The probability of retro areola positive histology increases with the tumour size. and was not related to the nodal status. The rate of local relapses was 0.9% per year. We didn’t find any significant difference in the local relapse rate according to different patient’s and tumour’s features. Most relapses were located close to the tumour bed but never in the NAC area. Conclusion Our study confirms that the local recurrence rate in the NSM completed with local radiotherapy on the NAC is not higher than the usual rate observed in the literature and the preservation of the NAC does not increase the risk. The absence of local recurrence in the region where a portion of glandular tissue has been purposely preserved is a good argument in favour of ELIOT.
Literatur
1.
Zurück zum Zitat Wellisch DK, Schain WS, Noone RB, Little JW 3rd (1987) The psychological contribution of nipple addition in breast reconstruction. Plast Reconstr Surg 80(5):699–704PubMedCrossRef Wellisch DK, Schain WS, Noone RB, Little JW 3rd (1987) The psychological contribution of nipple addition in breast reconstruction. Plast Reconstr Surg 80(5):699–704PubMedCrossRef
2.
Zurück zum Zitat Petit JY, Veronesi U, Orecchia R, Luini A, Rey P, Didier F, Giraldo A, Luini A, De Lorenzi F, Rietjens M, Garusi C, Intra M, Yamaguchi S, Martella S (2003) The nipple sparing mastectomy: early results of a feasability study of a new application of perioperative radiotherapy (ELIOT) in the treatment of breast cancer when mastectomy is indicated. Tumori 89:288–291PubMed Petit JY, Veronesi U, Orecchia R, Luini A, Rey P, Didier F, Giraldo A, Luini A, De Lorenzi F, Rietjens M, Garusi C, Intra M, Yamaguchi S, Martella S (2003) The nipple sparing mastectomy: early results of a feasability study of a new application of perioperative radiotherapy (ELIOT) in the treatment of breast cancer when mastectomy is indicated. Tumori 89:288–291PubMed
3.
Zurück zum Zitat Cense HA, Rutgers EJ, Lopes-Cardozo M, Van Lanschot JJ (2001) Nipple sparing mastectomy in breast cancer: a viable option? Eur J Surg Oncol 6:521–526CrossRef Cense HA, Rutgers EJ, Lopes-Cardozo M, Van Lanschot JJ (2001) Nipple sparing mastectomy in breast cancer: a viable option? Eur J Surg Oncol 6:521–526CrossRef
4.
Zurück zum Zitat Lambert PA, Kolm P, Perry RR (2000) Parameters that predict nipple involvement in breast cancer. J Am Coll Surg 191(4):354–359PubMedCrossRef Lambert PA, Kolm P, Perry RR (2000) Parameters that predict nipple involvement in breast cancer. J Am Coll Surg 191(4):354–359PubMedCrossRef
5.
Zurück zum Zitat Gajdos C, Tartter PI, Bleiweiss IJ (2000) Subareolar breast cancers. Am J Surg 180(3):167–170PubMedCrossRef Gajdos C, Tartter PI, Bleiweiss IJ (2000) Subareolar breast cancers. Am J Surg 180(3):167–170PubMedCrossRef
6.
Zurück zum Zitat Vyas JJ, Chinoy RF, Vaidya JS (1998) Prediction of nipple and areola involvement in breast cancer. Eur J Surg Oncol 24(1):15–16PubMedCrossRef Vyas JJ, Chinoy RF, Vaidya JS (1998) Prediction of nipple and areola involvement in breast cancer. Eur J Surg Oncol 24(1):15–16PubMedCrossRef
7.
Zurück zum Zitat Laronga C, Kemp B, Johnston D, Robb GL, Singletary SE (1999) The incidence of occult nipple-areola complex involvement in breast cancer patients receiving a skin sparing mastectomy. Ann Surg Oncol 6(6):609–613PubMedCrossRef Laronga C, Kemp B, Johnston D, Robb GL, Singletary SE (1999) The incidence of occult nipple-areola complex involvement in breast cancer patients receiving a skin sparing mastectomy. Ann Surg Oncol 6(6):609–613PubMedCrossRef
8.
Zurück zum Zitat Gerber B, Krause A, Reimer T et al (2003) Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure. Ann Surg 238(1):120–127PubMedCrossRef Gerber B, Krause A, Reimer T et al (2003) Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure. Ann Surg 238(1):120–127PubMedCrossRef
9.
Zurück zum Zitat Merrick HW, Battle JA, Padgett BJ, Dobelbower RR (1997) IORT for early breast cancer: a report on long-term results. Front Radiat Ther Oncol 31:126–130PubMedCrossRef Merrick HW, Battle JA, Padgett BJ, Dobelbower RR (1997) IORT for early breast cancer: a report on long-term results. Front Radiat Ther Oncol 31:126–130PubMedCrossRef
10.
Zurück zum Zitat DuBois J-B, Hay M, Gely S, Saint-Aubert B, Rouanet P, Pujol H (1997) IORT in breast carcinomas. Front Radiat Ther Oncol 31:131–137PubMedCrossRef DuBois J-B, Hay M, Gely S, Saint-Aubert B, Rouanet P, Pujol H (1997) IORT in breast carcinomas. Front Radiat Ther Oncol 31:131–137PubMedCrossRef
11.
Zurück zum Zitat Battle JA, DuBois J-B, Merrick HW, Dobelbower RR (1999) IORT for breast cancer. In: Gunderson LL et al (eds) Current clinical oncology: intraoperative irradiation: techniques and results. Humana Press Inc., New York, pp 521–526 Battle JA, DuBois J-B, Merrick HW, Dobelbower RR (1999) IORT for breast cancer. In: Gunderson LL et al (eds) Current clinical oncology: intraoperative irradiation: techniques and results. Humana Press Inc., New York, pp 521–526
12.
Zurück zum Zitat Veronesi U, Orecchia R, Luini A, Gatti G, Intra M, Zurrida S, Ivaldi G, Tosi G, Ciocca M, Tosoni A, De Lucia F (2001) A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer 37:2178–2183PubMedCrossRef Veronesi U, Orecchia R, Luini A, Gatti G, Intra M, Zurrida S, Ivaldi G, Tosi G, Ciocca M, Tosoni A, De Lucia F (2001) A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer 37:2178–2183PubMedCrossRef
13.
Zurück zum Zitat Veronesi U, Orecchia R, Luini A, Galimberti V, Gatti G, Intra M, Veronesi P, Leonardi MC, Ciocca M, Lazzari R, Caldarella P, Simsek S, Santos Silva L, Sances D (2005) Full-dose intraoperative radiotherapy with electrons durign breast conserving surgery. Experience with 590 cases. Ann Surg 242:101–106PubMedCrossRef Veronesi U, Orecchia R, Luini A, Galimberti V, Gatti G, Intra M, Veronesi P, Leonardi MC, Ciocca M, Lazzari R, Caldarella P, Simsek S, Santos Silva L, Sances D (2005) Full-dose intraoperative radiotherapy with electrons durign breast conserving surgery. Experience with 590 cases. Ann Surg 242:101–106PubMedCrossRef
14.
Zurück zum Zitat Veronesi U, Orecchia R, Luini A, Gatti G, Intra M, Veronesi P et al (2001) Focalised intraoperative irradiation after conservative surgery for early stage breast cancer. Breast 10(Supplement-3):84–89 Veronesi U, Orecchia R, Luini A, Gatti G, Intra M, Veronesi P et al (2001) Focalised intraoperative irradiation after conservative surgery for early stage breast cancer. Breast 10(Supplement-3):84–89
15.
Zurück zum Zitat Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef
16.
Zurück zum Zitat Smith J, Payne WS, Carney JA (1976) Involvement of the nipple and areola in carcinoma of the breast. Surg Gynecol Obstet 143(4):546–548PubMed Smith J, Payne WS, Carney JA (1976) Involvement of the nipple and areola in carcinoma of the breast. Surg Gynecol Obstet 143(4):546–548PubMed
17.
Zurück zum Zitat Andersen JA, Pallesen RM (1979) Spread to the nipple and areola in carcinoma of the breast. Ann Surg 189(3):367–372PubMedCrossRef Andersen JA, Pallesen RM (1979) Spread to the nipple and areola in carcinoma of the breast. Ann Surg 189(3):367–372PubMedCrossRef
18.
Zurück zum Zitat Cucin RL, Guthrie RH Jr, Luterman A, Gray G, Goulian D Jr (1980) Screening the nipple for involvement in breast cancer. Ann Plast Surg 5(6):477–479PubMedCrossRef Cucin RL, Guthrie RH Jr, Luterman A, Gray G, Goulian D Jr (1980) Screening the nipple for involvement in breast cancer. Ann Plast Surg 5(6):477–479PubMedCrossRef
19.
Zurück zum Zitat Andersen JA, Gram JB, Pallesen RM (1981) Involvement of the nipple and areola in breast cancer. Value of clinical findings. Scand J Plast Reconstr Surg 15(1):39–42PubMedCrossRef Andersen JA, Gram JB, Pallesen RM (1981) Involvement of the nipple and areola in breast cancer. Value of clinical findings. Scand J Plast Reconstr Surg 15(1):39–42PubMedCrossRef
20.
Zurück zum Zitat Schecter AK, Freeman MB, Giri D, Sabo E, Weinzweig J (2006) Applicability of the nipple-areola complex-sparing mastectomy: a prediction model using mammography to estimate risk of nipple-areola complex involvement in breast cancer patients. Ann Plast Surg 56(5):498–504, discussion 504PubMedCrossRef Schecter AK, Freeman MB, Giri D, Sabo E, Weinzweig J (2006) Applicability of the nipple-areola complex-sparing mastectomy: a prediction model using mammography to estimate risk of nipple-areola complex involvement in breast cancer patients. Ann Plast Surg 56(5):498–504, discussion 504PubMedCrossRef
21.
Zurück zum Zitat Vlajcic Z, Zic R, Stanec S, Lambasa S, Petrovecki M, Stanec Z (2005) Nipple-areola complex preservation: predictive factors of neoplastic nipple-areola complex invasion. Ann Plast Surg 55(3):240–244PubMedCrossRef Vlajcic Z, Zic R, Stanec S, Lambasa S, Petrovecki M, Stanec Z (2005) Nipple-areola complex preservation: predictive factors of neoplastic nipple-areola complex invasion. Ann Plast Surg 55(3):240–244PubMedCrossRef
22.
Zurück zum Zitat Lambert PA, Kolm P, Perry RR (2000) Parameters that predict nipple involvement in breast cancer. J Am Coll Surg 191(4):354–359PubMedCrossRef Lambert PA, Kolm P, Perry RR (2000) Parameters that predict nipple involvement in breast cancer. J Am Coll Surg 191(4):354–359PubMedCrossRef
23.
Zurück zum Zitat Friedman EP, Hall-Craggs MA, Mumtaz H, Schneidau A (1997) Breast MR and the appearance of the normal and abnormal nipple. Clin Radiol 52(11):854–861PubMedCrossRef Friedman EP, Hall-Craggs MA, Mumtaz H, Schneidau A (1997) Breast MR and the appearance of the normal and abnormal nipple. Clin Radiol 52(11):854–861PubMedCrossRef
24.
Zurück zum Zitat Palmieri B, Baitchev G, Grappolini S, Costa A, Benuzzi G (2005) Delayed nipple-sparing modified subcutaneous mastectomy: rationale and technique. Breast J 11(3):173–178PubMedCrossRef Palmieri B, Baitchev G, Grappolini S, Costa A, Benuzzi G (2005) Delayed nipple-sparing modified subcutaneous mastectomy: rationale and technique. Breast J 11(3):173–178PubMedCrossRef
25.
Zurück zum Zitat Govindarajulu S, Narreddy S, Shere MH, Ibrahim NB, Sahu AK, Cawthorn SJ (2006) Preoperative mammotome biopsy of ducts beneath the nipple areola complex. Eur J Surg Oncol 32(4):410–412PubMedCrossRef Govindarajulu S, Narreddy S, Shere MH, Ibrahim NB, Sahu AK, Cawthorn SJ (2006) Preoperative mammotome biopsy of ducts beneath the nipple areola complex. Eur J Surg Oncol 32(4):410–412PubMedCrossRef
Metadaten
Titel
Nipple-sparing mastectomy: risk of nipple-areolar recurrences in a series of 579 cases
verfasst von
J. Y. Petit
U. Veronesi
P. Rey
N. Rotmensz
E. Botteri
M. Rietjens
C. Garusi
F. De Lorenzi
S. Martella
R. Bosco
A. Manconi
A. Luini
V. Galimberti
P. Veronesi
G. B. Ivaldi
R. Orecchia
Publikationsdatum
01.03.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-9968-6

Weitere Artikel der Ausgabe 1/2009

Breast Cancer Research and Treatment 1/2009 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.